Navigation Links
Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations
Date:5/5/2011

PARSIPPANY, N.J., May 5, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that clinical and preclinical data highlighting the safety and efficacy of EXPAREL™ will be presented at two medical meetings.

New Phase 3 data on the use of EXPAREL in the treatment of postsurgical pain after augmentation mammoplasty will be presented by Sergio Bergese, M.D., associate professor of anesthesiology and neurological surgery, The Ohio State University, at the Society for Ambulatory Anesthesia (SAMBA) 26th Annual Meeting in San Antonio on Saturday, May 7, 2011. Dr. Bergese's presentation, titled "EXPAREL™ (Bupivacaine Extended-Release Liposome Injection), An Investigational Analgesic, Provides Postsurgical Pain Relief and Decreased Opioid Use as Demonstrated by Integrated Analysis" evaluated the extent and duration of the analgesic effect of EXPAREL in patients undergoing augmentation mammoplasty, the most commonly performed plastic surgery procedure in the United States.

Key findings from this study include:

  • A total of 136 patients were treated at 11 clinical sites in the U.S.
  • When the pain score and the opioid usage were combined using the integrated rank analysis of Silverman, statistical significance was achieved at multiple time points (p<0.05)
  • The mean total amount of opioid rescue used (morphine equivalents) was lower with EXPAREL at all time points through 96 hours
    • The difference between groups was statistically significant for the time intervals of 0–24 hours and 0–48 hours
  • The overall incidence of treatment-emergent adverse events was approximately 73% in both treatment groups
  • There were no serious adverse events, deaths or withdrawals from
    '/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
2. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
3. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
4. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
5. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
6. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
7. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
8. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
9. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
10. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
11. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014   Royal Philips ... today announced it has received 510(k) clearance from ... its precision planning application for Transcatheter Aortic-Valve Implantation ... application provides interventionalists with pre-procedural, high-precision positioning to ... TAVI planning application is available as part of ...
(Date:8/21/2014)... 2014   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... today announced positive results from a randomized, double-blind ... CCH) for the treatment of edematous fibrosclerotic panniculopathy ... 2a trial, all three doses of CCH (low ... improvement in the appearance of cellulite as measured ...
(Date:8/20/2014)... The National Association of Drug Diversion ... by the real-time, pseudoephedrine (PSE) blocking system in ... Exchange (NPLEx), automatically blocks unlawful pseudoephedrine sales and ... and make arrests. Data released by NPLEx shows ... blocked the sale of more than 7,481 boxes of ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR ... receiving concomitant systemic antibiotics in two Phase 3 clinical ... the treatment of adult patients with Clostridium difficile ... 1 issue of Clinical Infectious Diseases (CID). ...
... Aug. 16, 2011 Marshall Edwards, Inc. (Nasdaq: ... clinical development of novel therapeutics targeting cancer metabolism, announced ... ME-143 (formerly NV-143), the Company,s lead NADH oxidase inhibitor, ... Administration (FDA). The Company plans to initiate a Phase ...
Cached Medicine Technology:Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 2Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 3Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 4Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 5Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 6Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143 2Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143 3
(Date:8/22/2014)... 22, 2014 Dealing with a drug or ... the addict is a child. Adolescent substance abuse has been ... long time. But a new helpline is now providing a ... youth rehab for something like a teen drug addiction ... to help make a positive impact in the community. By ...
(Date:8/22/2014)... According to the market research report "Blind ... (ACC) System Market for Passenger Cars; by Geography ... by MarketsandMarkets, classifies and defines the automotive BSD ... and value. The report highlights potential growth opportunities ... review of the market drivers, restrains, growth indicators, ...
(Date:8/21/2014)... Petersburg, FL (PRWEB) August 22, 2014 The ... behind those fine lines, wrinkles and sagging of skin. ... loss. , "By age 40, the body has lost about ... has lost about 45%," says Kathy Heshelow, founder of Sublime ... with less of it - well, we know what happens." ...
(Date:8/21/2014)... York, NY (PRWEB) August 21, 2014 ... can often have larger discounts for specific protection plans, ... is now helping consumers to quote life insurance from ... , The local agents that appear inside of ... offer a fast method of price reviews this year. ...
(Date:8/21/2014)... 21, 2014 AVEC Health Solutions, ... the addition of Kerry Gillespie as Chief Executive ... management experience, Gillespie brings an extremely robust background ... management positions with prominent industry leading organizations across ... President of Triad Isotopes, Inc. a private nuclear ...
Breaking Medicine News(10 mins):Health News:Cincinnati’s New Troubled Teen Helpline is Making a Difference in the Community 2Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 2Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 3Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 4Health News:4 Skincare Products That Boost and Nurture Collagen on Sale at Sublime Beauty® 2Health News:4 Skincare Products That Boost and Nurture Collagen on Sale at Sublime Beauty® 3Health News:Life Insurance from Local Agents Now Priced Nationally Through Complimentary Tool Online 2Health News:Kerry Gillespie Appointed as Chief Executive Officer of AVEC Health Solutions 2
... was issued,today by the law firm of Schiffrin Barroway Topaz ... class action lawsuit was filed in the,United States District Court ... of securities of Healthways Inc. (Nasdaq: HWAY ),("Healthways" or ... (the "Class Period")., If you wish to discuss this ...
... The University of Illinois at Chicago is one of ... Norway to participate in the Clinical Islet Transplant Consortium ... researchers have begun clinical studies to test new approaches ... and fewer side effects for adults with difficult-to-control type ...
... U.S. Senate to vote soon on legislation that ... New Hampshire, WASHINGTON, July 8 Seniors ... to the Medicare Advantage,program in legislation being considered ... cut $6.6 million from the Medicare Advantage program ...
... Pittsburgh-led researchers could provide new insight into how ... arteriovenous malformations (AVMs)develop in humans, as reported in ... . , Led by Beth Roman, an assistant ... Arts and Sciences, the team created the first ...
... rates no different than ,watchful waiting, study shows , , ... therapy used for localized prostate cancer may not bestow ... with a simple "wait-and-see" approach. , Men taking androgen ... promote tumor growth, even had a slightly lower ...
... From the Committee to Reduce Infection Deaths (RID), ... to be,proud of," says Betsy McCaughey, Chairman of the ... of New York State. The New York,State Hospital-Acquired Infection ... performance with national infection,rate averages, and finds the state ...
Cached Medicine News:Health News:Shareholder Class Action Filed Against Healthways Inc. By The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Health News:Shareholder Class Action Filed Against Healthways Inc. By The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Health News:UIC in NIH-funded islet transplantation study for type 1 diabetes 2Health News:New Hampshire Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Pitt-led research provides insight into development of congenital circulatory defects 2Health News:Hormone Therapy Shows Little Benefit Against Prostate Cancer 2Health News:Hormone Therapy Shows Little Benefit Against Prostate Cancer 3Health News:It's the Same Old Song: 'Accentuate the Positive' as New York State Department of Health Releases Statewide Hospital Infection Rates 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: